IDiyas

For the Inventor, By the Inventor

Maynard, MA, United States of America

Gary O'Brien

USPTO Granted Patents = 9 

 

Average Co-Inventor Count = 10.6

ph-index = 3

Forward Citations = 46(Granted Patents)


Company Filing History:

goldMedal9 out of 3,923 
 
Novartis Ag
 patents

Years Active: 2014-2024

Loading Chart...
Loading Chart...
9 patents (USPTO):
1. 12172984 - Pyrazolopyridine derivatives and uses thereof (2024-12-24),
2. 12103919 - 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof (2024-10-01),
3. 11787785 - Pyrazolopyridine derivatives and uses thereof (2023-10-17),
4. 11566022 - 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof (2023-01-31),
5. 11229648 - 1,4-disubstituted pyridazine analogs thereof and methods for treating SMN-deficiency-related conditions (2022-01-25),
6. 10758533 - 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions (2020-09-01),
7. 10195196 - 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions (2019-02-05),
8. 9545404 - 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions (2017-01-17),
9. 8729263 - 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions (2014-05-20),

Title: Innovations of Gary O'Brien

Introduction

Gary O'Brien is a notable inventor based in Maynard, MA (US), recognized for his contributions to the field of pharmaceuticals. He holds a total of 9 patents, showcasing his innovative spirit and dedication to advancing medical science.

Latest Patents

Among his latest patents, O'Brien has developed compounds related to pyrazolopyridine derivatives. These compounds are significant for their potential use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels and inducing fetal hemoglobin (HbF) expression. This innovation is particularly relevant in the treatment of inherited blood disorders, such as sickle cell disease and beta-thalassemia. Another notable patent involves 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives, which share similar applications in addressing hemoglobinopathies.

Career Highlights

Gary O'Brien is currently employed at Novartis AG, a leading global healthcare company. His work focuses on developing pharmaceutical compositions that can significantly impact the treatment of blood disorders. His expertise and innovative approach have made him a valuable asset in the field of medical research.

Collaborations

O'Brien collaborates with talented professionals in his field, including John Ryan Kerrigan and Natalie Alysia Dales. These partnerships enhance the research and development process, leading to groundbreaking advancements in healthcare.

Conclusion

Gary O'Brien's contributions to pharmaceutical innovations demonstrate his commitment to improving health outcomes for patients with inherited blood disorders. His work continues to inspire advancements in medical research and treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…